M. Schrag

发表

Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site.

L. Wienkers, M. Schrag, 2001, Drug metabolism and disposition: the biological fate of chemicals.

TOPOLOGICAL ALTERATION OF THE CYP 3 A 4 ACTIVE SITE BY THE DIVALENT CATION MG 2 1

L. Wienkers, M. Schrag, 2000 .

Pharmacokinetics and Toxicokinetics

M. Schrag, K. Regal, 2013 .

Chapter 3 – Pharmacokinetics and Toxicokinetics

M. Schrag, K. Regal, 2013 .

Title : Phase 1 and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine / Cisplatin in Advanced Biliary Tract Cancer

Stacey, A. Khorana, A. Zhu, 2020 .

Benzodiazepine Binding Site Occupancy by the Novel GABAA Receptor Subtype-Selective Drug 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in Rats, Primates, and Humans

J. Baron, T. Fryer, D. Wong, 2010, Journal of Pharmacology and Experimental Therapeutics.

Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.

A. Coxon, D. Whittington, A. Tasker, 2008, Journal of medicinal chemistry.

Heterotropic modulation of sulfotransferase 2A1 activity by celecoxib: product ratio switching of ethynylestradiol sulfation.

B. Carr, E. Carlini, Catherine L. Booth-Genthe, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P1 and S1P5.

Jennifer E. Golden, R. Bürli, Matthew R. Lee, 2011, ACS medicinal chemistry letters.

Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains.

L. Wienkers, M L Schrag, L C Wienkers, 2001, Archives of biochemistry and biophysics.

Novel 5- and 6-subtituted benzothiazoles with improved physicochemical properties: potent S1P₁ agonists with in vivo lymphocyte-depleting activity.

Jennifer E. Golden, R. Bürli, K. Muller, 2012, Bioorganic & medicinal chemistry letters.

Discovery of a Potent, S1P3-Sparing Benzothiazole Agonist of Sphingosine-1-Phosphate Receptor 1 (S1P1).

Jennifer E. Golden, R. Bürli, M. Lobera, 2011, ACS medicinal chemistry letters.

Benzofuran Derivatives as Potent, Orally Active S1P1 Receptor Agonists: A Preclinical Lead Molecule for MS.

R. Bürli, M. Lobera, A. Saha, 2011, ACS medicinal chemistry letters.

Naphthamides as novel and potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: design, synthesis, and evaluation.

Ling Wang, Kelly Regal, Sesha Neervannan, 2008, Journal of medicinal chemistry.

Structural Characterization of Novel Adenine Dinucleotide Phosphate Conjugates of Imatinib in Incubations with Rat and Human Liver Microsomes

R. Subramanian, Shuguang Ma, Yang Xu, 2008, Drug Metabolism and Disposition.

Conjugates of Imatinib in Incubations with Rat and Human Liver Microsomes

R. Subramanian, Shuguang Ma, Yang Xu, 2008 .

Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.

Daniel J. Freeman, R. Wahl, J. McCarter, 2011, Journal of medicinal chemistry.

A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions.

Jeffrey P. Jones, A Rettie, W. Trager, 2000, Journal of medicinal chemistry.

Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol.

A. D. Rodrigues, Donghui Cui, B. Ma, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer

A. Khorana, A. Zhu, M. Kagey, 2020, Clinical Cancer Research.

Mechanism-based inactivation of cytochrome P450 2B1 by 7-ethynylcoumarin: verification of apo-P450 adduction by electrospray ion trap mass spectrometry.

L. Wienkers, P. Hollenberg, M. Schrag, 2000, Chemical research in toxicology.

Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.

A. D. Rodrigues, P. Lu, C. Raab, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Bacterial N-succinyl-L-diaminopimelic acid desuccinylase. Purification, partial characterization, and substrate specificity.

M. Gelb, Y. Lin, M. Schrag, 1988, The Journal of biological chemistry.

Topological alteration of the CYP3A4 active site by the divalent cation Mg(2+).

L. Wienkers, M. Schrag, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Solvent effect on cDNA-expressed human sulfotransferase (SULT) activities in vitro.

B. Ma, M. Shou, M. Schrag, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Discovery of amido-benzisoxazoles as potent c-Kit inhibitors.

E. Hu, R. Kunz, Shannon Rumfelt, 2008, Bioorganic & medicinal chemistry letters.

Catalytic turnover of pyrene by CYP3A4: evidence that cytochrome b5 directly induces positive cooperativity.

L. Wienkers, J. M. Hutzler, M. Schrag, 2005, Archives of biochemistry and biophysics.

Triazolam substrate inhibition: evidence of competition for heme-bound reactive oxygen within the CYP3A4 active site.

L. Wienkers, M. Schrag, 2001, Advances in Experimental Medicine and Biology.

Cytochrome P450 2C8 (CYP2C8)-mediated hydroxylation of an endothelin ETA receptor antagonist in human liver microsomes.

A. D. Rodrigues, B. Ma, R. Subramanian, 2004, Drug metabolism and disposition: the biological fate of chemicals.

Pyrene.pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site.

L. Wienkers, W. Atkins, M. Dabrowski, 2002, Journal of the American Chemical Society.